论文部分内容阅读
是否需要给予心血管疾病年风险率为1%的患者他汀治疗,这是近期扩大他汀治疗范围的热点问题。但是由于小型报刊等媒体与药物公司的推波助澜,该问题的讨论已经不适宜的简化成有关不良反应的争论。有人辩称,医学界人士在获得相关证据前不应该参与到这场风暴中,而且“普适性他汀治疗”这个命题过于宽泛,不能仅仅依靠消除潜在偏倚数据就可以回答,事实上这个问题需要社会多方面的努力。
The need for statin therapy in patients with an annual risk of cardiovascular disease of 1% is a hot issue for the recent expansion of statin therapy. However, due to the help of media and drug companies such as newspapers and periodicals, the discussion on this issue has been improperly reduced to controversy about adverse reactions. It has been argued that medical professionals should not be involved in the storm until the evidence is available and that the proposition “universal statin treatment” is too broad to rely on simply eliminating potential bias data. In fact, this The problem requires various social efforts.